These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

806 related items for PubMed ID: 31173106

  • 21. More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
    Zheng J, Wang H, Yao J, Zou X.
    Pharmazie; 2014 Jan; 69(1):38-42. PubMed ID: 24601221
    [Abstract] [Full Text] [Related]

  • 22. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
    Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R.
    J Clin Oncol; 2012 Mar 10; 30(8):777-82. PubMed ID: 22271473
    [Abstract] [Full Text] [Related]

  • 23. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
    Tanaka H, Yoshida M, Tanimura H, Fujii T, Sakata K, Tachibana Y, Ohwada J, Ebiike H, Kuramoto S, Morita K, Yoshimura Y, Yamazaki T, Ishii N, Kondoh O, Aoki Y.
    Clin Cancer Res; 2011 May 15; 17(10):3272-81. PubMed ID: 21558396
    [Abstract] [Full Text] [Related]

  • 24. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H, Cohen AL, Krishnakumar S, Wapnir IL, Veeriah S, Deng G, Coram MA, Piskun CM, Longacre TA, Herrler M, Frimannsson DO, Telli ML, Dirbas FM, Matin AC, Dairkee SH, Larijani B, Glinsky GV, Bild AH, Jeffrey SS.
    Breast Cancer Res; 2014 Apr 07; 16(2):R36. PubMed ID: 24708766
    [Abstract] [Full Text] [Related]

  • 25. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
    Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL.
    Breast Cancer Res; 2014 Jan 23; 16(1):R9. PubMed ID: 24451154
    [Abstract] [Full Text] [Related]

  • 26. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
    Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, Baselga J.
    Sci Transl Med; 2013 Jul 31; 5(196):196ra99. PubMed ID: 23903756
    [Abstract] [Full Text] [Related]

  • 27. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
    Kashiyama T, Oda K, Ikeda Y, Shiose Y, Hirota Y, Inaba K, Makii C, Kurikawa R, Miyasaka A, Koso T, Fukuda T, Tanikawa M, Shoji K, Sone K, Arimoto T, Wada-Hiraike O, Kawana K, Nakagawa S, Matsuda K, McCormick F, Aburatani H, Yano T, Osuga Y, Fujii T.
    PLoS One; 2014 Jul 31; 9(2):e87220. PubMed ID: 24504419
    [Abstract] [Full Text] [Related]

  • 28. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
    Cufí S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, López IÁ, Dorca J, Martínez S, López NB, Fernández SD, Cuyàs E, Visa J, Rodríguez-Gallego E, Quirantes-Piné R, Segura-Carretero A, Joven J, Martin-Castillo B, Menendez JA.
    Oncotarget; 2013 Sep 31; 4(9):1484-95. PubMed ID: 23986086
    [Abstract] [Full Text] [Related]

  • 29. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
    Mallon R, Hollander I, Feldberg L, Lucas J, Soloveva V, Venkatesan A, Dehnhardt C, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Gibbons J.
    Mol Cancer Ther; 2010 Apr 31; 9(4):976-84. PubMed ID: 20371716
    [Abstract] [Full Text] [Related]

  • 30. Preclinical Evaluation of a Fluorine-18 (18F)-Labeled Phosphatidylinositol 3-Kinase Inhibitor for Breast Cancer Imaging.
    Altine B, Gai Y, Han N, Jiang Y, Ji H, Fang H, Niyonkuru A, Bakari KH, Rajab Arnous MM, Liu Q, Zhang Y, Lan X.
    Mol Pharm; 2019 Nov 04; 16(11):4563-4571. PubMed ID: 31553879
    [Abstract] [Full Text] [Related]

  • 31. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
    Hu X, Xia M, Wang J, Yu H, Chai J, Zhang Z, Sun Y, Su J, Sun L.
    Biomed Pharmacother; 2020 Sep 04; 129():110397. PubMed ID: 32585451
    [Abstract] [Full Text] [Related]

  • 32. Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
    Citi V, Del Re M, Martelli A, Calderone V, Breschi MC, Danesi R.
    Cancer Chemother Pharmacol; 2018 Apr 04; 81(4):745-754. PubMed ID: 29476223
    [Abstract] [Full Text] [Related]

  • 33. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 Apr 04; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 34. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y, Morita TY, Ohashi A, Haeno H, Hakozaki Y, Fujii M, Kashima Y, Kobayashi SS, Mukohara T.
    Sci Rep; 2020 Dec 10; 10(1):21762. PubMed ID: 33303839
    [Abstract] [Full Text] [Related]

  • 35. GDC-0349 inhibits non-small cell lung cancer cell growth.
    Yang H, Zhao J, Zhao M, Zhao L, Zhou LN, Duan Y, Li G.
    Cell Death Dis; 2020 Nov 05; 11(11):951. PubMed ID: 33154352
    [Abstract] [Full Text] [Related]

  • 36. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
    Gris-Oliver A, Palafox M, Monserrat L, Brasó-Maristany F, Òdena A, Sánchez-Guixé M, Ibrahim YH, Villacampa G, Grueso J, Parés M, Guzmán M, Rodríguez O, Bruna A, Hirst CS, Barnicle A, de Bruin EC, Reddy A, Schiavon G, Arribas J, Mills GB, Caldas C, Dienstmann R, Prat A, Nuciforo P, Razavi P, Scaltriti M, Turner NC, Saura C, Davies BR, Oliveira M, Serra V.
    Clin Cancer Res; 2020 Jul 15; 26(14):3720-3731. PubMed ID: 32220884
    [Abstract] [Full Text] [Related]

  • 37. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
    Tzeng HE, Yang L, Chen K, Wang Y, Liu YR, Pan SL, Gaur S, Hu S, Yen Y.
    Oncotarget; 2015 May 10; 6(13):11061-73. PubMed ID: 25857298
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
    Clin Cancer Res; 2004 Dec 01; 10(23):8059-67. PubMed ID: 15585641
    [Abstract] [Full Text] [Related]

  • 39. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
    Mallon R, Feldberg LR, Lucas J, Chaudhary I, Dehnhardt C, Santos ED, Chen Z, dos Santos O, Ayral-Kaloustian S, Venkatesan A, Hollander I.
    Clin Cancer Res; 2011 May 15; 17(10):3193-203. PubMed ID: 21325073
    [Abstract] [Full Text] [Related]

  • 40. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A, Lee JE, Lee SS, Kim C, Lee SJ, Jang WS, Park S.
    Int J Cancer; 2013 Aug 15; 133(4):984-96. PubMed ID: 23475782
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.